ArticleJournal of gastrointestinal oncology2022

Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.

Yuhong Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.